The Psychedelic Science conference, coming to Denver this summer, plans to bring U.S. legislators, scientists, authors, mycologists and more together to discuss the new frontier of psychedelic ...

Still, almost despite itself, it points to true art. By Jason Farago and George Etheredge for The New York Times As a sprawling new exhibit opens in two museums in Amsterdam, the German artist ...

Algernon NeuroScience plans to use the proceeds to further its research and development initiatives, particularly in advancing its psychedelic DMT program for stroke and traumatic brain injury.

Byrd had recently finished art school at the Carnegie Institute ... Not necessarily a natural fit for a psychedelic light show. But Byrd had fallen on hard times after graduation, both personally ...

Algernon NeuroScience is a wholly-owned private subsidiary of Algernon Pharmaceuticals and has been established to advance its psychedelic DMT program for stroke and traumatic brain injury (TBI).

AGN Neuro intends to use proceeds from the offering to advance its R&D initiatives, including conducting a randomized, double-blind, placebo-controlled Phase 2a DMT study of 40 actual stroke ...